Notice of Results

RNS Number : 8184W
Cambridge Cognition Holdings PLC
20 April 2023
 

Cambridge Cognition Holdings Plc

 

(" Cambridge Cognition" or the "Company")

 

Notice of Results

 

Cambridge Cognition (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to confirm that it will announce the Company's preliminary financial results for the year ended 31 December 2022, on Wednesday 3 May 2023.

 

 

 

Enquiries

 

Cambridge Cognition Holdings Plc

Matthew Stork, Chief Executive Officer

Stephen Symonds, Chief Financial Officer 

 

Tel: 012 2381 0700

press@camcog.com

Panmure Gordon (UK) Limited (NOMAD and Joint Broker)

Freddy Crossley / Emma Earl 

Rupert Dearden 

 

Tel: 020 7886 2500 

(Corporate Finance) 

(Corporate Broking) 

Dowgate Capital Limited (Joint Broker)

David Poutney / James Serjeant 

 

Tel: 020 3903 7715

IFC Advisory Ltd (Financial PR and IR)

Tim Metcalfe / Graham Herring / Zach Cohen

Tel: 020 3934 6630

 cog@investor-focus.co.uk

 

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORBLGDSDXBDGXC
UK 100

Latest directors dealings